Because of the unique trial design of the Phase III TRAILBLAZER-ALZ 2 study, the FDA is seeking additional input regarding the safety and efficacy of donanemab for the treatment of early symptomatic Alzheimer disease.
Approval of Eli Lilly's Alzheimer Drug Donanemab Delayed as FDA Seeks More Information